Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

Ian McElree; Vignesh Packiam; Ryan Steinberg; Helen Hougen; Mohamad Abou Chakra; Sarah Mott; Michael A O’Donnell

doi:10.3390/cancers16244126

Back

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

Journal article

Open access

Peer reviewed

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

Ian McElree, Vignesh Packiam, Ryan Steinberg, Helen Hougen, Mohamad Abou Chakra, Sarah Mott and Michael A O’Donnell

Cancers, Vol.16(24), p.4126

01/01/2024

DOI: 10.3390/cancers16244126

PMCID: PMC11674833

PMID: 39766026

Files and links (1)

url

https://doi.org/10.3390/cancers16244126View

Published (Version of record) Open Access

Abstract

Simple Summary After failing multiple treatments for non-muscle invasive bladder cancer (NMIBC), patients with this disease face the prospect of radical bladder removal. However, many patients will wish to pursue additional bladder-sparing therapies or lack candidacy for such an invasive procedure. We aimed to report on a tertiary intravesical regimen of sequential doxorubicin and gemcitabine alternating weekly with docetaxel and mitomycin (Quad Chemo) for patients with high-risk NMIBC failing multiple previous treatments. We found in a population of 29 patients with 39 treated units (bladder and/or upper urinary tracts), 80% of the units were disease-free at 3 months and 43% were disease-free at 2 years following Quad Chemo treatment. However, disease progression was a concern with an estimated 43% of patients experiencing disease progression at 5 years. Lastly, side effects were not uncommon with 19 (66%) patients reporting any side effect and 7 (24%) ultimately stopping Quad Chemo due to side effects.

Chemotherapy

Metastasis

Urogenital System

Biopsy

Bladder

Cancer therapies

Cellular biology

Doxorubicin

Gemcitabine

Invasiveness

Mitomycin

Patients

Side effects

Surveillance

Toxicity

Urological surgery

Urothelial cancer

Urothelial carcinoma

Details

Title: Subtitle: Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma
Creators: Ian McElree - University of Iowa
Vignesh Packiam - Rutgers Cancer Institute
Ryan Steinberg - University of Iowa, Urology
Helen Hougen - University of Iowa
Mohamad Abou Chakra - University of Iowa
Sarah Mott - University of Iowa
Michael A O’Donnell - University of Iowa, Urology
Resource Type: Journal article
Publication Details: Cancers, Vol.16(24), p.4126
DOI: 10.3390/cancers16244126
PMID: 39766026
PMCID: PMC11674833
eISSN: 2072-6694
Publisher: MDPI AG
Grant note: John & Carol Walter Family FoundationNational Institute of Health Cancer Center Support Grant: 3P30CA086862-22S1
This work was supported by the John & Carol Walter Family Foundation and the National Institute of Health Cancer Center Support Grant Project Number 3P30CA086862-22S1.
Language: English
Date published: 01/01/2024
Academic Unit: Urology
Record Identifier: 9984759992602771

Metrics

5 Record Views

4 Times Cited - Web of Science